

SECTION I AMENDMENTS

IN THE CLAIMS:

Please amend claims 20, 21, 22, 24, 26, and 27 as set forth below.
Please add new claim 31, as presented below.

Complete Listing of the Claims

Upon entry of the present amendment, the claims will stand as follows. The following listing of the claims will replace all prior versions and listings of the claims in the present application:

Claims 1-19 (**Canceled**).

20. **(Currently Amended)** A conjugate suited for treating prokaryotic infections, comprising the following components:
 - (a) a phage-holin protein as transport peptide or protein adapted to penetrate ~~the prokaryotic cell membrane~~ the infectious prokaryote; and linked by a covalent bond thereto; ~~and~~
 - (b) a peptide nucleic acid (PNA) to be introduced into the prokaryote and directed against a DNA of a gene giving antibiotic resistance, wherein the peptide nucleic acid inhibits the transcription of the gene.

21. **(Currently amended)** The conjugate according to claim 20, wherein the ~~bacterium~~ prokaryote is a bacterium pathogenic for humans.

22. **(Currently amended)** The conjugate according to claim 20, wherein the ~~transport peptide or protein~~ is a phage-holin protein comprising comprises one of the amino acid sequences of SEQ ID NOs: 4 to 31.

23. **(Previously Presented)** The conjugate according to claim 20, wherein the antibiotic resistance is a resistance to penicillin, ampicillin, kanamycin or tetracycline.

24. **(Currently amended)** The conjugate according to claim 20, which has the following structure: ~~transport peptide or protein~~ phage-holin protein-spacer-~~peptide nucleic acid~~ (PNA).

25. **(Previously Presented)** The conjugate or conjugate mixture according to claim 24, wherein the spacer is polylysine, polyglycine or poly(glycine/lysine).
26. **(Currently amended)** The conjugate according to claim 24, wherein the spacer is linked to the ~~transport peptide or protein~~ phage-holin protein via a cleavable disulfide bridge.
27. **(Currently amended)** The conjugate according to claim 20, wherein the ~~peptide-nucleic-acid~~ PNA comprises the sequence H₂N-ATTGTTAGATTTCAT-COOH (SEQ ID NO:1).
28. **(Canceled)**
29. **(Previously Presented)** A medicament comprising the conjugate according to claim 20.
30. **(Previously Presented)** The medicament according to claim 29, further comprising at least one antibiotic for which the prokaryote was re-sensitized by administering the conjugate.
31. **(New)** A conjugate suited for treating prokaryotic infections, comprising the following components:
 - (a) a peptide selected from the group consisting of SEQ ID NOs: 4 to 31; and linked by a covalent bond thereto;
 - (b) a peptide nucleic acid (PNA) to be introduced into the infectious prokaryote and directed against a gene giving antibiotic resistance.

THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK